Oncotelic Therapeutics Inc (OTLC)

$0.07 0.00 (-2.40%)
Market Cap 29.48M
Revenue (ttm) 0.00
Net Income (ttm) -4.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.72
Volume 283,300
Avg Vol 138,156
Day's Range N/A - N/A
Shares Out 442.60M
Stochastic %K 0%
Beta -0.66
Analysts Strong Buy
Price Target $4.00

Company Profile

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatme...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 635 7000
Fax: 650 635 7001
Address:
29397 Agoura Road, Suite 107, Agoura Hills, United States
ckruel
ckruel Mar. 20 at 4:39 PM
$OTLC this also should bring inst. investment
0 · Reply
ckruel
ckruel Mar. 20 at 4:38 PM
$OTLC this is from the analyst who has the $4 target . Read the last line, this event is gearing for the near future along with the reevaluation of OTLC’s balance sheet when the 45. Percent is applied, that is why I’m buying down here. OTLC: As we reported in our March 31 research note, OTLC entered into a joint venture, or JV, with Dragon Overseas Capital Ltd. (Dragon Overseas) and GMP Biotechnology Ltd. (GMP Bio). Dragon Overseas and GMP Bio are affiliated with Golden Mountain Partners (GMP). GMP Bio also has a wholly owned subsidiary, Sapu Therapeutics, LLC, which in turn has two wholly owned subsidiaries, namely Sapu Bioscience, LLC and Sapu Holdings, LLC. The plan of the JV is to develop and ultimately market OT-101, individually and/or in combination with other products, along with its JV partners. Also, the JV is intended to go public through an IPO at some time in the future. OTLC owns 45% of the JV and on its public debut could add multiples to the company’s market cap.
0 · Reply
ckruel
ckruel Mar. 16 at 6:51 PM
$OTLC volume 3 x the daily avg at 917,000
0 · Reply
ckruel
ckruel Mar. 16 at 5:17 PM
$OTLC Balance Sheet Action: Oncotelic has initiated an ASC-compliant valuation to determine how much of this new valuation can be formally recognized on its balance sheet. The company indicated that if this assessment confirms a higher value, they will record an upward adjustment, which would potentially lead to a "major fair-value uptick" and a "meaningful increase" in total assets and shareholder equity. Timing: The co. planned to complete this second independent U.S.-based valuation to support the remeasurement of its 45% equity interest as part of its forward-looking strategy entering 2026. This revaluation is designed to reflect the matured progress of Oncotelic's Deciparticle™ nanomedicine platform (specifically Sapu-003) and its transition toward financial recognition. The company is still navigating significant financial hurdles, including a low market cap and high dilution risk from convertible debt, which the co. is attempting to manage alongside this revaluation.
0 · Reply
ckruel
ckruel Mar. 16 at 5:14 PM
$OTLC Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is actively working to revalue its company based on a new, higher independent valuation of its joint venture (JV) partnership with GMP Bio. Financial Post Financial Post +1 Based on updates from late 2025 and early 2026, here is the breakdown of the revaluation: New Partnership Valuation: A third-party analysis (by Frost & Sullivan) of the GMP Bio joint venture pipeline, completed in Nov 2025, valued it at approximately $1.7 billion. Oncotelic's Implied Value: With a 45% stake in GMP Bio, Oncotelic’s proportional implied asset value is estimated at roughly $765 million.
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 16 at 12:29 PM
$OTLC
0 · Reply
ckruel
ckruel Mar. 12 at 7:49 PM
$OTLC Just under 610 k vol so far today, twice the avg daily……
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 5 at 2:23 AM
$OTLC Dr Treiu with all of his scam companies....never could be successful with his brain so just scams the system...
0 · Reply
NewsAndFilings
NewsAndFilings Mar. 4 at 7:17 PM
Growth Stocks: $NGTF, $AMLM, $CSDX, $OTLC, $ECGI Across Robotics, Precious Metals, MedTech and Blockchain https://thestreetreports.com/growth-stocks-ngtf-amlm-csdx-otlc-ecgi-across-robotics-precious-metals-medtech-and-blockchain/
2 · Reply
ckruel
ckruel Mar. 3 at 2:50 PM
$OTLC gosh are you actually short still at this price, manure, what a loser.
0 · Reply
Latest News on OTLC
No data available.
ckruel
ckruel Mar. 20 at 4:39 PM
$OTLC this also should bring inst. investment
0 · Reply
ckruel
ckruel Mar. 20 at 4:38 PM
$OTLC this is from the analyst who has the $4 target . Read the last line, this event is gearing for the near future along with the reevaluation of OTLC’s balance sheet when the 45. Percent is applied, that is why I’m buying down here. OTLC: As we reported in our March 31 research note, OTLC entered into a joint venture, or JV, with Dragon Overseas Capital Ltd. (Dragon Overseas) and GMP Biotechnology Ltd. (GMP Bio). Dragon Overseas and GMP Bio are affiliated with Golden Mountain Partners (GMP). GMP Bio also has a wholly owned subsidiary, Sapu Therapeutics, LLC, which in turn has two wholly owned subsidiaries, namely Sapu Bioscience, LLC and Sapu Holdings, LLC. The plan of the JV is to develop and ultimately market OT-101, individually and/or in combination with other products, along with its JV partners. Also, the JV is intended to go public through an IPO at some time in the future. OTLC owns 45% of the JV and on its public debut could add multiples to the company’s market cap.
0 · Reply
ckruel
ckruel Mar. 16 at 6:51 PM
$OTLC volume 3 x the daily avg at 917,000
0 · Reply
ckruel
ckruel Mar. 16 at 5:17 PM
$OTLC Balance Sheet Action: Oncotelic has initiated an ASC-compliant valuation to determine how much of this new valuation can be formally recognized on its balance sheet. The company indicated that if this assessment confirms a higher value, they will record an upward adjustment, which would potentially lead to a "major fair-value uptick" and a "meaningful increase" in total assets and shareholder equity. Timing: The co. planned to complete this second independent U.S.-based valuation to support the remeasurement of its 45% equity interest as part of its forward-looking strategy entering 2026. This revaluation is designed to reflect the matured progress of Oncotelic's Deciparticle™ nanomedicine platform (specifically Sapu-003) and its transition toward financial recognition. The company is still navigating significant financial hurdles, including a low market cap and high dilution risk from convertible debt, which the co. is attempting to manage alongside this revaluation.
0 · Reply
ckruel
ckruel Mar. 16 at 5:14 PM
$OTLC Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is actively working to revalue its company based on a new, higher independent valuation of its joint venture (JV) partnership with GMP Bio. Financial Post Financial Post +1 Based on updates from late 2025 and early 2026, here is the breakdown of the revaluation: New Partnership Valuation: A third-party analysis (by Frost & Sullivan) of the GMP Bio joint venture pipeline, completed in Nov 2025, valued it at approximately $1.7 billion. Oncotelic's Implied Value: With a 45% stake in GMP Bio, Oncotelic’s proportional implied asset value is estimated at roughly $765 million.
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 16 at 12:29 PM
$OTLC
0 · Reply
ckruel
ckruel Mar. 12 at 7:49 PM
$OTLC Just under 610 k vol so far today, twice the avg daily……
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 5 at 2:23 AM
$OTLC Dr Treiu with all of his scam companies....never could be successful with his brain so just scams the system...
0 · Reply
NewsAndFilings
NewsAndFilings Mar. 4 at 7:17 PM
Growth Stocks: $NGTF, $AMLM, $CSDX, $OTLC, $ECGI Across Robotics, Precious Metals, MedTech and Blockchain https://thestreetreports.com/growth-stocks-ngtf-amlm-csdx-otlc-ecgi-across-robotics-precious-metals-medtech-and-blockchain/
2 · Reply
ckruel
ckruel Mar. 3 at 2:50 PM
$OTLC gosh are you actually short still at this price, manure, what a loser.
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 3 at 2:48 PM
$OTLC wheres pumper Chris with his unlicensed financial advice telling everyone to buy Dr Trieus baggies????
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 3 at 4:03 AM
$OTLC down 10% and Chris says buy everyone....somethings cooking 🤣
0 · Reply
ckruel
ckruel Mar. 3 at 3:10 AM
$OTLC $OTLC vol ended at 528,000 …. Almost double the avg vol….keep saying there’s something cooking with the retracting of the partnership and uplifting. It will take awhile to get done, anyways doubled my holdings while it’s in the basement being accumulated., maybe I’m right, maybe not, just my speculation….
2 · Reply
ckruel
ckruel Mar. 2 at 8:10 PM
$OTLC the shares short was for a diff stock, my mistake, the vol is correct for today
1 · Reply
ckruel
ckruel Mar. 2 at 7:58 PM
$OTLC $OTLC $OTLC Short interest has dropped today by half a mill approximately , avg vol 294,939, todays vol. currently 515,330 so far
0 · Reply
Mauisurfrider
Mauisurfrider Mar. 2 at 3:01 PM
$OTLC no real volume here, just Dr Trieu playin with his poo.
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 23 at 8:06 PM
BioMedNewsBreaks – $OTLC Featured In NetworkNewsAudio On Biotech M&A Trends https://ibn.fm/uCjD7
0 · Reply
Mauisurfrider
Mauisurfrider Feb. 23 at 3:42 PM
$OTLC
1 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 20 at 7:52 PM
BioMedNewsBreaks – $OTLC Featured in BioMedWire Editorial on CNS and Oncology Momentum https://ibn.fm/KBmLj
0 · Reply
ckruel
ckruel Feb. 20 at 3:48 PM
$OTLC https://finance.yahoo.com/news/oncotelic-therapeutics-inc-otcqb-otlc-133000233.html
1 · Reply
Mauisurfrider
Mauisurfrider Feb. 20 at 3:03 PM
$OTLC check out their office on Google!! 30 employees my a s s. All Dr Trieus family members and fellow scammers.
0 · Reply
Mauisurfrider
Mauisurfrider Feb. 20 at 3:00 PM
$OTLC
0 · Reply